Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis

Background: Alemtuzumab is a highly effective drug for the treatment of multiple sclerosis (MS), characterized by specific patterns of depletion and repopulation. As an induction-like treatment concept, two mandatory infusion courses can inhibit long-term disease activity in the majority of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Akgün, Katja, Blankenburg, Judith, Marggraf, Michaela, Haase, Rocco, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005935/
https://www.ncbi.nlm.nih.gov/pubmed/32082320
http://dx.doi.org/10.3389/fimmu.2020.00056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005935/
https://www.ncbi.nlm.nih.gov/pubmed/32082320
http://dx.doi.org/10.3389/fimmu.2020.00056

Ejemplares similares